Genetic and Clinical Insights into ALS/FTD: Profiling a Rare Cohort to Explore Spectrum Heterogeneity
Authors:
- Ana MarjanovicAMAna Marjanovic
- Elka StefanovaESElka Stefanova
- Vanja ViricVVVanja Viric
- Aleksa PalibrkAPAleksa Palibrk
- Gorana Mandić StojmenovićGSGorana Mandić Stojmenović
- Tanja StojkovićTSTanja Stojković
- Lenka StojadinovicLSLenka Stojadinovic
- Ivana BastaIBIvana Basta
- Ivana NovakovicINIvana Novakovic
- Zorica StevićZSZorica Stević
- Milena JankovicMJMilena Jankovic
Open Access
- 28 September 2025
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (10) , 451
Abstract
Background: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are recognized as a spectrum of neurodegenerative disorders with overlapping clinical, pathological, and genetic features. The identification of C9orf72 hexanucleotide repeat expansion as the most common genetic cause of both conditions has prompted further investigation of genetic modifiers that may contribute to disease heterogeneity. We aimed to analyze the frequency of C9orf72 repeat expansions and potential modifying roles of APOE, ATXN1, and ATXN2 in Serbian ALS/FTD patients. Methods: Our study included an ALS/FTD cohort (n = 22) and healthy controls (n = 94). Repeat sizing in C9orf72, ATXN1 and ATXN2 was performed by fluorescent polymerase chain reaction (PCR) and capillary electrophoresis, while repeat-primed PCR was used to confirm C9orf72 expansions. APOE genotyping was conducted using real-time PCR assays targeting SNPs rs429358 and rs7412. Results: In the ALS/FTD cohort, 31.82% of the patients had heterozygous C9orf72 repeat expansion. The most common APOE genotype among patients was ε3/ε3 (72.73%). Intermediate-length ATXN1 alleles (32–44 repeats) were detected in 13.64% of patients and ATXN2 intermediate-length alleles (27–33 repeats) were found in 9% of patients. No significant differences were observed between ALS/FTD patients and controls in APOE ε4 frequency or intermediate ATXN1/ATXN2 repeats. Conclusions: Larger, population-specific studies and meta-analyses are needed to better understand the role of genetic modifiers in ALS/FTD pathogenesis and their influence on clinical heterogeneity. By integrating genetic and clinical data, this study represents a step toward the development of precision medicine strategies for ALS/FTD.Keywords
Funding Information
- Ministry of Science, Technological Development and Innovation, Republic of Serbia (451-03-137/2025-03/200110)
This publication has 50 references indexed in Scilit:
- Frequency of C9orf72, GRN, and MAPT pathogenic variants in patients recruited at the Belgrade Memory Centerneurogenetics, 2024
- Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European CountriesJAMA Neurology, 2023
- C9orf72 repeat length might influence clinical sub-phenotypes in dementia patientsNeurobiology of Disease, 2022
- CAG repeats ≥ 34 in Ataxin-1 gene are associated with amyotrophic lateral sclerosis in a Brazilian cohortJournal of the Neurological Sciences, 2020
- Prevalence of Carriers of Intermediate and Pathological Polyglutamine Disease–Associated Alleles Among Large Population-Based CohortsJAMA Neurology, 2019
- Delineating the relationship between amyotrophic lateral sclerosis and frontotemporal dementia: Sequence and structure-based predictionsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2016
- The Role ofAPOEin the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral SclerosisJAMA Neurology, 2016
- Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: A meta‐analysisAlzheimer's & Dementia, 2013
- The apolipoprotein E ε4 allele is not a significant risk factor for frontotemporal dementiaAnnals of Neurology, 1998
- Apolipoprotein E ϵ4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosisAnnals of Neurology, 1995